Jasim Saade Abdalkareem, Pallathadka Harikumar, Sivaprasad G V, Kumar Ashwani, Mustafa Yasser Fakri, Mohammed Jaafaru Sani, Eldesoqui Mamdouh, Pramanik Atreyi, Abdukarimovna Rakhimova Khusnidakhon, Zwamel Ahmed Hussein
Medical Laboratory Techniques Department, College of Health and Medical Technology, University of Al-maarif, Anbar, Iraq.
Manipur International University, Imphal, Manipur, India.
Funct Integr Genomics. 2025 Mar 25;25(1):72. doi: 10.1007/s10142-025-01584-3.
One characteristic that makes gastric cancer (GC) against other cancers is the intricate immune system's reaction, particularly to tenacious inflammation. Consequently, the immunological function is essential to the growth of this malignancy. Tumor immunotherapy has yielded several encouraging outcomes, but despite this, different patients continue to not respond to treatment, and a far larger number become resistant to it. Also, activated CAR-T cells express a majority of immunological checkpoint factors, containing PD1, CTLA4, and LAG3, which counteracts the anti-tumor actions of CAR-T cells. Moreover, cytokine release syndrome is one of the possible adverse responses of CAR-T cell therapy. Therefore, producing universal allogeneic T lymphocytes with potent anti-tumor activity is essential. This study demonstrates current research on this cutting-edge technology, including the composition and mode of action of CAR-NK and CAR-T cells in GC. Also, in this study, we examined recent studies about various specific GC biomarkers that target CAR-T cells and CAR-NK cells.
胃癌（GC）与其他癌症相比的一个特点是复杂的免疫系统反应，尤其是对顽固炎症的反应。因此，免疫功能对这种恶性肿瘤的生长至关重要。肿瘤免疫疗法已经产生了一些令人鼓舞的结果，但尽管如此，不同的患者仍然对治疗没有反应，而且更多的患者对其产生耐药性。此外，活化的CAR-T细胞表达大多数免疫检查点因子，包括PD1、CTLA4和LAG3，这抵消了CAR-T细胞的抗肿瘤作用。此外，细胞因子释放综合征是CAR-T细胞疗法可能的不良反应之一。因此，产生具有强大抗肿瘤活性的通用异基因T淋巴细胞至关重要。本研究展示了对这项前沿技术的当前研究，包括CAR-NK和CAR-T细胞在GC中的组成和作用方式。此外，在本研究中，我们研究了关于靶向CAR-T细胞和CAR-NK细胞的各种特定GC生物标志物的近期研究。
